PORTAGE BIOTECH INC (PRTG) Stock Price, Quote, News and Overview
NASDAQ:PRTG - Nasdaq - VGG7185A1369 - Common Stock - Currency: USD
PRTG Quote, Performance and Key Statistics
PORTAGE BIOTECH INC
NASDAQ:PRTG (1/31/2025, 8:00:00 PM)
After market: 5.39 +0.98 (+22.22%)4.41
-0.15 (-3.29%)
The current stock price of PRTG is 4.41 USD. In the past month the price decreased by -14.7%. In the past year, price decreased by -68.94%.
PRTG Latest News, Press Releases and Analysis
Which stocks are moving after the closing bell on Friday?
After the closing bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Portage Biotech Announces Completion of $2.15 Million Private Financing
On January 29, 2025, Portage Biotech Inc. (the “Company”) completed the sale of 524,390 ordinary shares for aggregate proceeds of US$2,150,000....
Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company
Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company...
Portage Biotech Announces Letter of Intent with Immunova for an Option to Acquire iOx Therapeutics, Ltd
Portage Biotech Announces Letter of Intent with Immunova for an Option to Acquire iOx Therapeutics, Ltd...
PRTG Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.11 | 324.98B | ||
| AMGN | AMGEN INC | 14.85 | 153.42B | ||
| GILD | GILEAD SCIENCES INC | 21.94 | 121.14B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 905.25 | 118.90B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.81 | 73.95B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.17B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.99B | ||
| BNTX | BIONTECH SE-ADR | N/A | 29.83B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.95B | ||
| NTRA | NATERA INC | N/A | 23.36B | ||
| BIIB | BIOGEN INC | 8.81 | 20.97B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 15.86B |
Related stock screener links
About PRTG
Company Profile
Portage Biotech Inc is a VG-based company operating in Biotechnology industry. Portage Biotech Inc. is a clinical-stage immuno-oncology company. The firm is engaged in advancing therapies to improve long-term treatment response, and quality of life in patients with cancers. The Company’s access to technologies coupled with biological mechanisms enables the identification of clinical therapies and product development strategies, which accelerate these medicines through the translational pipeline. The Company’s portfolio consists of four platforms, with lead programs consisting of invariant natural killer T-cell (iNKT) engagers and a suite of treatments targeting the adenosine pathway. Within these four platforms, the Company has nine product candidates, of which five are pre-clinical and four of which are clinical stage. The Company’s portfolio also includes small molecule adenosine inhibitors, such as PORT-6, PORT-7, PORT-8 and PORT-9, which represent targeting the adenosine pathway.
Company Info
PORTAGE BIOTECH INC
Clarence Thomas Building, P.O. Box 4649, Road Town
Tortola ONTARIO VG1110 VG
CEO: Ian Walters
Employees: 7
Company Website: https://portagebiotech.com/
Investor Relations: http://ir.portagebiotech.com
Phone: 4167377600
PRTG FAQ
What is the stock price of PRTG?
The current stock price of PRTG is 4.41 USD.
What is the symbol for PORTAGE BIOTECH INC stock?
The exchange symbol of PORTAGE BIOTECH INC is PRTG and it is listed on the Nasdaq exchange.
On which exchange is PRTG stock listed?
PRTG stock is listed on the Nasdaq exchange.
Is PRTG a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for PRTG, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of PRTG.
Does PRTG stock pay dividends?
PRTG does not pay a dividend.
When does PRTG stock report earnings?
PRTG will report earnings on 2025-02-26.
What is the Price/Earnings (PE) ratio of PRTG?
PRTG does not have a PE ratio as the earnings reported over the last twelve months were negative (-129.8).
What is the Short Interest ratio of PRTG stock?
The outstanding short interest for PRTG is 3.62% of its float.
PRTG Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to PRTG. When comparing the yearly performance of all stocks, PRTG is a bad performer in the overall market: 94.86% of all stocks are doing better.
PRTG Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PRTG. The financial health of PRTG is average, but there are quite some concerns on its profitability.
PRTG Financial Highlights
Over the last trailing twelve months PRTG reported a non-GAAP Earnings per Share(EPS) of -129.8. The EPS decreased by -403.1% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1357.19% | ||
| ROE | -2830.59% | ||
| Debt/Equity | 0 |
PRTG Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to PRTG. The Buy consensus is the average rating of analysts ratings from 6 analysts.